Accord BioPharma Inc.
NDC labeler code: 69448
What is a labeler?
The company whose name is on the package and in the FDA’s National Drug Code (NDC) Directory. It may make the medicine itself or sell medicine made by another company. The first part of every NDC code identifies the labeler.
Official FDA data only
Products, approvals and recalls come from the FDA (NDC Directory, Drugs@FDA, enforcement reports). Recalls are linked to this company by the NDC labeler code on the recalled product.
Questions about your medicine: ask your doctor or pharmacist. In an emergency, call 911.
Prescription medicines
- Ustekinumab-srlfImuldosa · 3 products
- Pegfilgrastim-cbqvUdenyca, Neulasta, Stimufend · 3 products
- MitomycinMutamycin · 2 products
- FilgrastimNivestym, Granix, Releuko · 2 products
- Trastuzumab-strfHercessi · 2 products
- LeuprolideCamcevi, Camcevi Etm · 2 products
- DenosumabBomyntra, Osenvelt, Xtrenbo · 2 products
FDA applications for these products
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
- BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
| Approved | Application | Medicine | Sponsor |
|---|---|---|---|
| January 15, 2026 | BLA761027 | Filgrastim FILKRI | Accord Biopharma Inc. |
| October 29, 2025 | BLA761424 | Denosumab JUBEREQ, OSVYRTI | Accord Biopharma Inc. |
| October 10, 2024 | BLA761364 | Ustekinumab-srlf IMULDOSA | Accord Biopharma Inc. |
| April 25, 2024 | BLA761346 | Trastuzumab-strf HERCESSI | Accord Biopharma Inc. |
| May 25, 2021 | NDA211488 | Leuprolide CAMCEVI KIT | Accord |
| November 2, 2018 | BLA761039 | Pegfilgrastim-cbqv UDENYCA | Coherus Biosciences Inc |
| April 30, 1998 | ANDA064144 | Mitomycin MITOMYCIN | Accord Hlthcare |
The sponsor is the company that holds the FDA application; it can differ from the labeler.
Recall timeline
2026
-
June 10, 2026 · Class II · Ongoing · D-0653-2026 · Ustekinumab-srlf
Lack of assurance of Sterility:
IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single dose vial, Manufactured by Accord BioPharma Inc., 8041 Arco corporate Drive, Suite 200, Raleigh, NC 27617, USA, Manufactured at: Catalent Ind
-
January 16, 2026 · Class I · Ongoing · D-0353-2026 · Pegfilgrastim-cbqv
Temperature Abuse. 116 cartons with specific serial numbers of Lot 2199821, were stored incorrectly in a controlled room temperature environment instead of the required refrigerated environment.
UDENYCA, pegfilgrastim-cbqv injection, 6 mg/0.6mL Single Dose Prefilled Syringe, Rx only, Manufactured by Accord BioPharma, Inc., 8041 Arco Corporate Drive, Suite 200, Raleigh, NC 27617, NDC 69448-025-63
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Next steps
- Find a pharmacy near youAsk which company made your medicine and whether it is recalled
- Latest FDA drug recallsAll companies, newest first
- All drug companiesA to Z
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026